drugset / Trial / NCT06674759

Efficacy and Safety of Tongren-Dahuoluo Bolus in Patients with Knee Osteoarthritis

NCT06674759 ↗

RandomizedCrossoverDouble-blindTreatment

Summary

The clinical trial has a research cycle of 24 weeks. The first 12 weeks are multicenter, randomized, double-blind, controlled trials. A total of 72 patients with knee osteoarthritis with liver-kidney deficiency syndrome and/or cold-dampness arthralgia syndrome are planned to be enrolled and randomly assigned to the control group (Tongren-Dahuoluo Bolus) and the treatment group (Tongren-Dahuoluo Bolus Placebo) in a 1:1 ratio. The purpose is to compare the safety and efficacy of Tongren-Dahuoluo Bolus and placebo in treating knee osteoarthritis. A long-term blind extension study will be conducted in the next 12 weeks. All subjects will take Tongren-Dahuoluo Bolus orally to evaluate the long-term safety, tolerability, and efficacy of Tongren-Dahuoluo Pills in treating patients with knee osteoarthritis.

Timeline

Start
2025-01-10
Primary completion
2025-06-30
Completion
2025-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tongren-Dahuoluo Bolus Unknown 0.72 g Oral

Indications